Kids' Cancer-Drug Shortage Averted

Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

The announcement applies to all currently approved therapies, both BCMA-directed and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell treatments.

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.

A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.